Parameter
| Biomarker | Telomerase and telomerase complex | Full name | Telomerase and telomerase complex | Molecular Type | protein/nucleic acid |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | prognosis, therapeutic targets | ||
| Disease | Multiple Myeloma (MM) | Disease Subtypes | / | ||
| Organ | Bone marrow, Serum | Test Sample / Technology Platform | Marrow, serum | ||
| Pathobiological Mechanisms | Telomerase activation maintains unlimited proliferation; TRF2 abnormalities lead to chromosomal instability and promote clonal evolution | ||||
| Clinical Availability Status | research and verification phase | ||||
| Notes and Dynamics | Patients with high TERT expression exhibited a 30% reduction in median OS; telomerase inhibitor MST-312 induced apoptosis in MM cells, showing synergistic efficacy when combined with lenalidomide. | ||||